Fig. 1From: Genetic and immunological biomarkers predict metastatic disease recurrence in stage III colon cancera Proportion of patients with oncogenic mutations in KRAS exon 2, mutations in BRAF exon 15, and microsatellite instable (MSI-H) tumors. Gene expression levels of osteopontin, SASH1, and MACC1. Matched non-diseased colon mucosa (n = 33 for KRAS-, BRAF- and MSI-analysis, and n = 79 for mRNA expression) and stage III colon cancer (n = 83). mut, mutated; MMR, mismatch repair; MSS, microsatellite stable; N, normal colon tissue; T, tumor; wt, wild type; analysis by t test. b Staining for Tumor-infiltrating T-cells (TILs) by immunocytochemistry on tissue sections. c Intratumoral densities of CD3 and CD8 T-cells, threshold for prognostic analysis. d Density of CD3 and CD8 TILs is highly significantly correlated (p < 0.0001; Spearman)Back to article page